Taku Shigesawa
Hokkaido University(JP)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Hepatitis C virus research, Hepatocellular Carcinoma Treatment and Prognosis, Hepatitis B Virus Studies, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling(2020)74 cited
- → Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection(2020)59 cited
- → Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria(2020)44 cited
- → Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan(2020)43 cited
- → Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting(2019)43 cited
- → Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis(2019)42 cited
- → Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people(2020)42 cited
- → Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B(2022)35 cited
- → Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria(2021)32 cited
- → Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication(2022)25 cited